| __timestamp | Alnylam Pharmaceuticals, Inc. | Corcept Therapeutics Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 34916000 |
| Thursday, January 1, 2015 | 60610000 | 36949000 |
| Friday, January 1, 2016 | 89354000 | 45240000 |
| Sunday, January 1, 2017 | 199365000 | 62416000 |
| Monday, January 1, 2018 | 382359000 | 81289000 |
| Tuesday, January 1, 2019 | 479005000 | 100359000 |
| Wednesday, January 1, 2020 | 588420000 | 105326000 |
| Friday, January 1, 2021 | 620639000 | 122356000 |
| Saturday, January 1, 2022 | 770658000 | 152848000 |
| Sunday, January 1, 2023 | 795646000 | 184259000 |
| Monday, January 1, 2024 | 975526000 |
Data in motion
In the ever-evolving landscape of the pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Alnylam Pharmaceuticals, Inc. and Corcept Therapeutics Incorporated have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade.
From 2014 to 2023, Alnylam Pharmaceuticals has seen a staggering increase in SG&A expenses, growing by approximately 1,700%. This reflects their aggressive expansion and investment in market presence. In contrast, Corcept Therapeutics has experienced a more moderate increase of around 430%, indicating a more conservative approach.
These trends highlight differing strategic priorities: Alnylam's focus on rapid growth and market penetration versus Corcept's steady, controlled expansion. Investors and industry analysts should consider these financial strategies when evaluating the long-term potential and risk profiles of these companies.
SG&A Efficiency Analysis: Comparing AbbVie Inc. and Corcept Therapeutics Incorporated
Operational Costs Compared: SG&A Analysis of Novartis AG and Alnylam Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Corcept Therapeutics Incorporated
Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.
Alnylam Pharmaceuticals, Inc. and Viatris Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Corcept Therapeutics Incorporated
Comparing SG&A Expenses: Bio-Techne Corporation vs Corcept Therapeutics Incorporated Trends and Insights
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Corcept Therapeutics Incorporated
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Rhythm Pharmaceuticals, Inc.
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs ACADIA Pharmaceuticals Inc. Trends and Insights
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc. Trends and Insights